Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

63.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
 
Via Benzinga
Where Gilead Sciences Stands With Analysts
Over the past 3 months, 10 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
After all, if you got a health problem, you're going to do whatever is necessary to get treatment. Demand for these products is inelastic and growing. And that means a long runway for revenue, profit,... 
Via Talk Markets
Why These Analysts Are Bullish On Gilead's Q1 Earnings
 
Via Benzinga
Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion
The company said quarterly sales rose 2% excluding the impact of Veklury. 
Via Investor's Business Daily
Recap: Gilead Sciences Q1 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Stocks Are Undervalued
The bear growled this past week as the S&P 500 Index skirted the (-20%) threshold. But Friday the markets bounced back, much to investors’ relief. The Index is still in a correction, although that may... 
Via Talk Markets
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped. 
Via Investor's Business Daily
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings
 
Via Benzinga
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
 
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet. 
Via Benzinga
Pfizer: The Treasure of Albert Bourla
Pfizer won the lottery with Covid-19, but how it invests that cash will determine how well the stock does in the longer-term. 
Via InvestorPlace
May 2022 Stock Considerations
Let’s take a look at my May stock considerations. 
Via Talk Markets
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market... 
Via Benzinga
Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus
Gilead Sciences, Inc. (NASDAQ: GILD) reported firs 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gilead Sciences's Earnings Outlook
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Dividend Stocks Paying Over 5% to Buy Now
Stock markets will return less this year as interest rates rise and cause a recession, so investors should demand higher yield. 
Via InvestorPlace
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Backs Pfizer's Oral COVID Antiviral Therapy For High-Risk Patients
 
Via Benzinga
Pfizer: What Comes After the Covid-19 Fire?
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy
 
Via Benzinga
If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market... 
Via Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.